Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quality of life and toxicity comparison of imatinib versus nilotinib in chronic myeloid leukemia
ChiCTR-OCH-11001699Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of imatinib and nilotinib in chronic myelogenous leukemia (CML) (2 cohorts), sponsored by Peking University People's Hospital. Primary endpoint: SF-36 health survey. Started May 2011; status: completed.
02
Drugs
imatinibnilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR-OCH-11001699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCH-11001699.